Something huge is going to be happening soon at the U.S. Food and Drug Administration (FDA) … it is all anticipation about the transition of government.
…
That’s because the only prospective candidates for FDA Commissioner are from the world of venture capital, a sector that plays a big role in drug development. Trump is said to be looking for new thinking to change government from Silicon Valley billionaire Peter Thiel.
Thiel owns Mithril Capital Management, where Jim O’Neill is managing director and an apparent candidate for FDA Commissioner.
Another is Balaji Srinivasan, a partner in the venture capital firm Andreessen Horowitz. Both met with Trump as recently as last week. A third possibility is former FDA deputy commissioner Dr. Scott Gottlieb, now a resident fellow at the American Enterprise Institute.
…
There are several steps that must occur … First, the Senate will have to complete action on Rep. Tom Price’s confirmation as Secretary of Health and Human Services. Next, Trump will have to nominate the next FDA Commissioner, who will then be subjected to the kind of examination that the cabinet appointments have gone through. How the Senators feel about quicker approvals is certain to be tested. Are they going to be faster approvals…or are they going to remain in the comfort of Big Pharma’s pocket?
The GLP aggregated and excerpted this blog/article to reflect the diversity of news, opinion, and analysis. Read full, original post: Letter From The Editor: Huge Change for FDA
